Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 2

NCT ID: NCT03229200 Enrolling by invitation - Solid Tumor Clinical Trials

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Start date: May 22, 2017
Phase: Phase 4
Study type: Interventional

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib studies, are still benefitting from treatment with ibrutinib, and have no access to commercial ibrutinib for their underlying disease within their region.

NCT ID: NCT01804686 Enrolling by invitation - Clinical trials for Chronic Lymphocytic Leukemia

A Long-term Extension Study of PCI-32765 (Ibrutinib)

CAN3001
Start date: September 9, 2013
Phase: Phase 3
Study type: Interventional

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

NCT ID: NCT00846157 Enrolling by invitation - Clinical trials for Diffuse Large B-cell Lymphoma

Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients

NKCell
Start date: September 2007
Phase: Phase 3
Study type: Interventional

Primary objective: - To compare the event free survival for 3years of R-CHOP plus Biocell Natural Killer Cell to R-CHOP therapy with DLBCL patients.